20th week of 2017 patent applcation highlights part 8 |
Patent application number | Title | Published |
20170135978 | Acetylcholinesterase Inhibitors for Treatment of Dermatological Conditions - Embodiments of the invention involve treating skin afflictions by the topical or oral use of acetylcholinesterase inhibitor. By effectively reducing or eliminating the population of | 2017-05-18 |
20170135979 | PDE-DELTA INHIBITOR FOR THE TREATMENT OF CANCER - The present invention relates to the administration of a novel compound advantageously efficacious as PDEδ inhibitor and its effects on subjects with cancer. More specifically, the present invention is directed to a method for administering a compound having favorable geometric properties for interacting with the PDEδ prenyl-binding pocket, namely has certain structural components such as a three-cyclic backbone and at least one benzoyl-moiety in a side chain having at least two substituents containing highly electronegative atoms and being linked to the backbone via an aliphatic chain, for treating a subject suffering from a disease such as cancer, in particular non-small-cell lung cancer. The presence of said structural components particularly contributes to an advantageous interaction with PDEδ, in particular with amino acids deep in the binding pocket. The present invention further provides a method to target tumor cells harboring an RAS gene mutation as well as pharmaceutical compositions comprising said compound. | 2017-05-18 |
20170135980 | PREDICTING RESPONSE TO CANCER THERAPY - The present invention relates to cancer markers that are predictive for cancer patent response to treatment with an m TOR inhibitor and a vascular disrupting agent. The present invention further relates to methods of treating a cancer patient subpopulation with a combination of an m TOR inhibitor and a vascular disrupting agent. | 2017-05-18 |
20170135981 | Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor - Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor via the co-administration of a dipeptidyl peptidase IV (DPP IV) inhibitor. Additionally, methods are provided for normalizing the glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor via the co-administration of a dipeptidyl peptidase IV (DPP IV) inhibitor. The present invention also relates to methods for treating diabetes, especially Type 2 diabetes, as well as hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis and related diseases, comprising administering an SGLT2 inhibitor and a dipeptidyl peptidase IV (DPP IV) inhibitor. | 2017-05-18 |
20170135983 | COMPOSITION FOR REGULATING BLOOD SUGAR - The present invention provides a composition for regulating blood sugar. The composition comprises at least one yellow pigment extracted from a red mold product, wherein the said yellow pigment is Monascin, Ankaflavin, or combination of Monascin and Ankaflavin. Moreover, results of a variety of animal experiments have proved that this blood sugar regulating composition indeed possess the functionalities of: lowering Hyperglycemia induced by high energy diet, alleviating ROS and inflammatory caused by the Hyperglycemia, reduce AST and ALT value of liver as well as sarcosine value of kidney. | 2017-05-18 |
20170135985 | THERAPEUTIC/ PREVENTIVE AGENT CONTAINING COUMARIN DERIVATIVE AS ACTIVE INGREDIENT - A method for prophylactically or therapeutically treating an inflammatory disease and/or degenerative intervertebral disk disease in a subject is disclosed. The method includes administering to the subject an effective amount of a coumarin derivative represented by formula (I), or a pharmaceutically acceptable salt or hydrate thereof: | 2017-05-18 |
20170135986 | STABILIZED MULTI-FUNCTIONAL ANTIOXIDANT COMPOUNDS AND METHODS OF USE - Disclosed are novel stable compounds having anti-oxidant properties and methods of using the compounds for the treatment of diseases or injuries associated with oxidative stress. | 2017-05-18 |
20170135987 | THIOUREYLENE LIQUID COMPOSITIONS - The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats. | 2017-05-18 |
20170135988 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA - Traction alopecia and other disorders related to mechanical pulling on hair are treated or prevented by administering a topical composition comprising an alpha-1 adrenergic receptor agonist, a muscarinic receptor agonist, a nicotinic receptor agonist, and/or a cholinesterase inhibitor, or electrical stimulation to contract the arrector pili muscle. Compositions and methods are disclosed herein for the treatment and prevention of hair loss disorders caused at least in part by repeated application of tensile force to hair, including, without limitation, traction alopecia. | 2017-05-18 |
20170135989 | ALLISARTAN ISOPROXIL SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION - The present invention provides an allisartan isoproxil solid dispersion with high drug loading and stability. On that basis, it also provides an allisartan isoproxil pharmaceutical composition containing mentioned solid dispersion. Compared with available technologies, the mentioned allisartan isoproxil pharmaceutical composition is characterized by high stability, good dissolution performance, and improved patient compliance, etc. | 2017-05-18 |
20170135990 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 5,5-FUSED HETEROARYLENE FLAVIVIRIDAE INHIBITOR AND THEIR USE FOR TREATING OR PREVENTING FLAVIVIRIDAE INFECTION - Provided herein are spray-dried particles comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound and methods of their preparation. Also provided herein are pharmaceutical compositions comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, method of their preparation, and their use for treating or preventing hepatitis C virus infection. | 2017-05-18 |
20170135991 | NANOPARTICULATE FORMULATION COMPRISING A mPGES-1 INHIBITOR - The present invention relates to a nanoparticulate formulation comprising a microsomal prostaglandin E synthases-1 (“mPGES-1”) inhibitor. Particularly, the present invention relates to a nanoparticulate formulation comprising an mPGES-1 inhibitor and one or more surface stabilizers; a process for preparing such formulation; and its use in treating pain and inflammation in a subject. | 2017-05-18 |
20170135992 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY - The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases. | 2017-05-18 |
20170135993 | PHARMACEUTICAL COMPOSITION CONTAINING FK506 DERIVATIVE FOR TREATING FUNGAL INFECTION CAUSED BY GENUS CRYPTOCOCCUS AND GENUS CANDIDA AND USE THEREOF - The present invention relates to a pharmaceutical composition containing FK506 derivative for treating a fungal infection caused by the genus | 2017-05-18 |
20170135994 | NAMPT INHIBITORS - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. | 2017-05-18 |
20170135995 | PHARMACEUTICAL COMPOSITIONS OF BERBERINE WITH EPA AND DHA, AND METHODS THEREOF - The invention provides various novel compositions of berberine in combination with pharmacologically active EPA and DHA, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, dyslipidemia in statin-intolerance patients, diabetes, diabetic complications, hypercholesterolemia, or obesity. Additionally, the pharmaceutical compositions of the invention are useful in treating and/or preventing atherosclerosis, heart diseases, neurodegenerative diseases, inflammation, cancers, as well as various liver diseases or disorders, such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver. Furthermore, the pharmaceutical compositions of the invention are useful in improving liver functions in chronic viral associated liver diseases and alcohol-related liver diseases. | 2017-05-18 |
20170135996 | PHARMACEUTICAL DEPOT FOR N-{5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL)-3-FLUORO-4-(PYRIDIN-2-Y- LMETHOXY)BENZAMIDE - A pharmaceutical depot comprising (i) N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (PA) and (ii) a polymer which degrades to create an acidic microclimate, wherein the PA is released from the polymer upon polymer degradation. | 2017-05-18 |
20170135997 | TREATMENT OF FAMILIAL EXUDATIVE VITREORETINOPATHY THROUGH S1PR2 INHIBITION - Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the administration of a therapeutically effective amount of a Sphingosine-1-phosphate receptor type 2 (S1PR2) inhibitor. | 2017-05-18 |
20170135998 | Aminopyridine Based Buffers with Wide Buffering Ranges, Antibiotics and Myelin Disease Therapy - Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be buffered. Aminopyridines channel blocking, combined with buffering and zwitterionic charge states make promising therapies for myelin diseases and as antibiotics. | 2017-05-18 |
20170135999 | CONTROLLED RELEASE FORMULATIONS HAVING RAPID ONSET AND RAPID DECLINE OF EFFECTIVE PLASMA DRUG CONCENTRATIONS - The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval. | 2017-05-18 |
20170136000 | METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS - The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof. | 2017-05-18 |
20170136001 | METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS - The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome P-450, or a pharmaceutically acceptable salt thereof. | 2017-05-18 |
20170136002 | Composition Containing Apomorphine And A Divalent Metal Cation - A composition containing apomorphine and a divalent metal cation, such as, for example, Zn | 2017-05-18 |
20170136003 | TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD - This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease. | 2017-05-18 |
20170136005 | METHODS OF TREATING OPIATE DEPENDENCY AND PREVENTING NON-ORAL OPIATE ABUSE AMONG OPIATE ADDICTS - The present invention relates to the use of an inseparable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for treatment of opiate dependency in humans and to the use of an inseparable combination of an opiate and at least one opiate antagonists with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for prevention of non-oral opiate abuse in opiate addicts. | 2017-05-18 |
20170136006 | METHODS OF MANUFACTURING ORAL DOSAGE FORMS - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 2017-05-18 |
20170136007 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - Disclosed are novel piperazine derivatives that act as agonists of the a7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds. | 2017-05-18 |
20170136008 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER - A method of treating ovarian cancer in a subject afflicted therewith comprising administering to the subject an effective amount of an anti-cancer agent and an effective amount of a compound having the structure: | 2017-05-18 |
20170136009 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS - The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: | 2017-05-18 |
20170136010 | ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE AND METHOD FOR PRODUCING ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE - [Object] An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that exhibits high bioavailability and high dissolubility even in persons having low stomach acid, and that can also ensure dissolubility after being allowed to stand for a certain period of time. Another object is to provide a simple method for producing the oral solid preparation. | 2017-05-18 |
20170136011 | TREATMENT AND PROGNOSTIC MONITORING OF CANCEROUS PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS - The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy. | 2017-05-18 |
20170136012 | TREATMENT AND PROGNOSTIC MONITORING OF NON-CANCEROUS PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS - The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy. | 2017-05-18 |
20170136013 | Method of Treating Hand-Foot Syndrome and Symptoms Associated Therewith - A method of treating hand-foot syndrome (palmar-plantar erythrodysesthesia) and symptoms associated therewith in a patient undergoing or scheduled to undergo chemotherapy is claimed. The method involves topically administering a pharmaceutical composition comprising an effective amount of an alpha adrenergic receptor agonist, pharmaceutically acceptable salt thereof, or combinations thereof; and a pharmaceutically acceptable carrier to the affected areas of skin or to the hands and feet. | 2017-05-18 |
20170136014 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor - Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a PI3K-δ inhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, PI3K-δ inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer. | 2017-05-18 |
20170136015 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PSORIASIS - Pharmaceutical compositions for topical administration for the treatment of psoriasis are described, containing as active ingredient therapeutically effective quantities of 4,6-dimethyl-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine (I) and 2,4-O-(2-furanylmethylene)-1,3,5,6-tetra-O-methyl-D-glucitol combined with suitable excipients and/or diluents. | 2017-05-18 |
20170136016 | METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION - A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years | 2017-05-18 |
20170136017 | LIVER X RECEPTOR MODULATORS - Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described. | 2017-05-18 |
20170136018 | Methods for Treating MS Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity - The present invention provides methods of treating MS using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK). | 2017-05-18 |
20170136019 | sGC STIMULATORS - Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. | 2017-05-18 |
20170136020 | COMPOSITIONS COMPRISING DASATINIB FOR TREATING COMPLEX REGIONAL PAIN SYNDROME - Oral dosage forms of osteoclast inhibitors, including some Bruton's tyrosine kinase (BTK) inhibitors, such as dasatinib can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome. | 2017-05-18 |
20170136021 | METHODS AND COMPOSITIONS FOR TREATING ENVELOPED VIRUSES - Described are compositions and methods for treating an enveloped virus in a patient in need thereof. Exemplary enveloped viruses are those in the family Filoviridae and include Ebola virus. | 2017-05-18 |
20170136022 | SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITOR - A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of N4-(4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and uses thereof are provided herein. | 2017-05-18 |
20170136023 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - The invention relates to a quinazoline derivative represented by the general formula (I), a pharmaceutical acceptable salt and a stereoisomer thereof as tyrosine kinase inhibitor, wherein R | 2017-05-18 |
20170136024 | INHIBITORS OF E1 ACTIVATING ENZYMES - This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia. | 2017-05-18 |
20170136025 | PHARMACEUTICAL PREPARATION CONTAINING ENTECAVIR AS ACTIVE INGREDIENT, AND PREPARATION METHOD THEREFOR - The present invention relates to a pharmaceutical preparation comprising entecavir as an active ingredient, wherein an antioxidizing agent is added to enhance stability of entecavir, and a method for preparing the same. According to the present invention, the invention has an effect that entecavir can be stably maintained in a pharmaceutical preparation containing a certain amount or more of moisture by adding the antioxidizing agent, thereby a pharmaceutical preparation can be provided as a formulation containing a certain amount or more of moisture, for example, an orally disintegrating film formulation. | 2017-05-18 |
20170136026 | COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE - Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2017-05-18 |
20170136027 | Aprepitant Injectable Formulations - An aqueous stable and ready-to-use formulation of aprepitant is prepared. Especially preferred formulations comprise a synergistic combination of a co-solvent and a surfactant and may further include a secondary co-solvent. Among other advantages of contemplated formulations, aprepitant is dissolved at high concentrations and remains dissolved and stable, even over prolonged periods of time. | 2017-05-18 |
20170136028 | COMPOSITION AND METHOD FOR COMPOUNDED THERAPY - A method of compounding a transdermal cream may include grinding one or more tablets of a Non-Steroidal Anti-Inflammatory Drug (NSAID) and one or more nerve depressants, anticonvulsants, or combinations thereof to produce a fine powder. The find powder may be wetted and added to an eutectic mixture of lidocaine and prilocaine in an emulsified topical cream in the form of a lidocaine 2.5%-prilocaine 2.5% cream. The compounded transdermal may include between 0.05% and 0.15% by weight meloxicam, between 1.0% and 5.0% by weight gabapentin, and at least 80% by weight of the lidocaine 2.5%-prilocaine 2.5% cream. | 2017-05-18 |
20170136029 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE - The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided. | 2017-05-18 |
20170136030 | TREATMENT OF MALARIA USING INHIBITORS OF THE ISPD ENZYME IN THE NON-MEVALONATE PATHWAY - Compounds are disclosed that inhibit the methylerythritol cytidyltransferase (IspD) enzyme in the non-mevalonate pathway (MEP pathway), which is present in many organisms including the | 2017-05-18 |
20170136031 | PLATINUM COMPLEXES AS ANTICANCER AGENTS - Novel compounds comprising a Pt(II) metal center and S-containing ligands as anticancer agents including tetrakis(1,3-diazinane-2-thione)platinum(II) chloride monohydrate complex [Pt(Diaz) | 2017-05-18 |
20170136032 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC SYNDROME - Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): | 2017-05-18 |
20170136033 | STABLE FORMULATIONS OF TESTOSTERONE UNDECANOATE - The present invention is directed to stable pharmaceutical formulations. More specifically, the present invention is directed to stable pharmaceutical formulations of testosterone undecanoate. | 2017-05-18 |
20170136034 | PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC - Dry powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta | 2017-05-18 |
20170136035 | PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC - Dry powder formulations for inhalation containing a combination of an anti-cholinergic, a long-acting beta | 2017-05-18 |
20170136036 | Method for providing regular contraception - The invention relates to a method for providing regular contraception to a woman. Said method comprises administering a daily contraceptive amount of ulipristal acetate or a metabolite thereof over a period of at least 21 consecutive days. | 2017-05-18 |
20170136037 | PHARMACEUTICAL COMPOSITION AND USE - An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided. | 2017-05-18 |
20170136038 | Sulfated-Oxysterol and Oxysterol Sulfation by Hydroxysterol Sulfotransferase Promote Lipid Homeostasis and Liver Tissue Regeneration - Methods and compositions for the prevention and treatment of liver damage or disease in a subject in need thereof are provided. The methods involve providing the sulfated oxysterol 25-hydroxycholesterol-3-sulfate (25HC3S) to the subject e.g. by 1) administering 25HC3S to the subject; or 2) overexpressing, in the subject, the hydroxysterol sulfotransferase enzyme SULT2B1b, which catalyzes the sulfation of 25-hydroxycholesterol (25HC) to form 25HC3S. | 2017-05-18 |
20170136039 | METHODS AND COMPOSITIONS OF BILE ACIDS AND SALTS FOR REDUCTION OF FAT - The present invention relates to compositions and methods for treating fat deposit accumulation in a subject. The invention provides a non-surgical method for reducing fat deposits comprising administering an effective amount of a fat-lysing concentration of one or more of cholate and chenodeoxycholate in a pharmaceutically acceptable formulation to the subject in need thereof. | 2017-05-18 |
20170136040 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 2017-05-18 |
20170136041 | METHOD OF IMPROVING THE MUSCLE QUALITY OF OBESE AND/OR SARCOPENIC MAMMALS USING PHYTOECDYSONES - Phytoecdysones for use in improving muscle quality in obese and/or sarcopenic mammals, preferably, obese mammals subjected to a low-calorie diet. The phytoecdysones are advantageously incorporated into a food composition. The phytoecdysones can be derived from plants, such as quinoa. | 2017-05-18 |
20170136042 | Methods and Compositions for Treating Cancer - Methods and compositions for treating cancer are described herein. More particularly, the methods tor treating cancer comprise administering a 17α-hydroxylase/C | 2017-05-18 |
20170136043 | THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY - Uses of pyrrolopyrimidines with anti-Mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK−/− tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms. | 2017-05-18 |
20170136044 | METHOD OF TREATING PRE-CANCEROUS LESIONS WITH GLYPHOSATE, AND COMPOSITIONS THEREOF - A method for treating a pre-cancerous skin lesion on a human subject with glyphosate is described, along with compositions for said treatment. | 2017-05-18 |
20170136045 | DI-ISOPROPYL-PHOSPHINOYL-ALKANES AS TOPICAL AGENTS FOR THE TREATMENT OF SENSORY DISCOMFORT - The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms); post-operative hypothermia; post-anaesthetic shivering; nasal congestion and nasal obstruction; pharyngeal and esophageal discomfort; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The applicant has found that localized delivery of DIPA compounds to the upper eyelid and/or facial skin has an alerting and enhancement effect on behavior and can be used to give a cosmetic refreshing look, to mental alertness, to reduce fatigue, and to improve work output. The present discovery also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy, in diagnosis of neuropathic pain, and in study of TRPM8 function. | 2017-05-18 |
20170136046 | COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME - Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome. | 2017-05-18 |
20170136047 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. | 2017-05-18 |
20170136048 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY - The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase. | 2017-05-18 |
20170136049 | USE OF PURIFIED 2'-FUCOSYLLACTOSE, 3-FUCOSYLLACTOSE AND LACTODIFUCOTETRAOSE AS PREBIOTICS - The invention provides compositions and methods for utilizing synthetic human milk oligosaccharides as prebiotics. | 2017-05-18 |
20170136050 | ANTI-GLYCATION METHODS AND COMPOSITIONS - The present invention comprises compositions that provide anti-glycation activity comprising a mineral extract composition or a mogroside/mineral extract composition or a mogroside composition. Such compositions are useful for methods of preventing, treating and inhibiting the effects of glycation in the body. The methods of the present invention comprise use of anti-glycation composition for the treatment and prevention of glycation related conditions including diabetes, atherosclerosis, arthritis, mental conditions and vision impairment. | 2017-05-18 |
20170136051 | METHODS AND FORMULATIONS FOR TREATING SIALIC ACID DEFICIENCIES - The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations. | 2017-05-18 |
20170136052 | THERAPEUTIC COMBINATIONS OF CURCUMINOIDS AND FLAVONOIDS - Provided is a formulation and a method associated therewith for treating inflammation. The formulation includes therapeutically effective amounts of curcuminoids and two flavonoids. The two flavonoids include baicalin and catechin. | 2017-05-18 |
20170136053 | NOVEL PHARMACEUTICAL COMPOSITION AND USES THEREOF - Pharmaceutical compositions containing a combination of NPM inhibitor and anti-cancer agent are disclosed. Methods of inhibiting or reducing the growth of cancer cells in a subject, by administering an effective amount of nucleophosmin (NPM) inhibitor and one or more anti-cancer agents, whereby the symptoms and signs of cancer in the subject are reduced are also provided. | 2017-05-18 |
20170136054 | MODIFIED STARCH MATERIAL OF BIOCOMPATIBLE HEMOSTASIS - A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal. | 2017-05-18 |
20170136055 | COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND MIPOMERSEN AND METHODS OF USE THEREOF - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 2017-05-18 |
20170136056 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS - Described herein are methods of disrupting (e.g., reducing the viscosity of, or dissolving) a preformed biofilm in a subject, the method comprising: administering to the subject an effective amount of a composition comprising a soluble chitosan or derivatized chitosan wherein the soluble chitosan or deritvatized chitosan when administered contacts the preformed biofilm, thereby disrupting (e.g., reducing the viscosity of, or dissolving) the preformed biofilm. | 2017-05-18 |
20170136057 | OPHTHALMIC COMPOSITIONS WITH IMPROVED DESSICATION PROTECTION AND RETENTION - The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound. | 2017-05-18 |
20170136058 | CO-NETWORK OF HIGH AND LOW MOLECULAR WEIGHT 3-ARM STAR CYANOACRYLATE-TELECHELIC POLYISOBUTYLENE AND 2-OCTYL CYANOACRYLATE - In one or more embodiments, the present invention relates to a substantially homogeneous miscible liquid adhesive composition comprising a relatively high number average molecular weight (M | 2017-05-18 |
20170136059 | TOPICAL NITRIC OXIDE SYSTEMS AND METHODS OF USE THEREOF - The present invention generally relates to compositions and methods for transdermal drug delivery. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction, treating wounds, or causing or promoting hair growth. For example, in one aspect, the present invention is generally directed to compositions for delivery of nitric oxide, transdermally and/or to a mucosal surface. The composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances. In some embodiments, a composition comprising nitric oxide is unexpectedly stable and can be stored long-term. Thus, for example, a composition of the invention may exhibit a long shelf life, with little loss or reaction of nitric oxide. This may be particularly useful for certain applications such as consumer products, including those described herein. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2017-05-18 |
20170136060 | TREATMENT OF VAGINITIS - Treatment of vaginal mycoses, bacterial vaginoses, and other forms of the vaginitis (inflammation of the vagina) by clinoptilolite having a particle size of between 0.2 and 10 μm. Clinoptilolite, when used externally, is effective in the treatment of these vaginal disorders in mammals and humans, and also for restoring a healthy vaginal microbiota. The clinoptilolite may be used with one or more of the following adjuvants: pharmaceutically acceptable carrier materials, viable microorganisms and/or extracts thereof, nutrients for the healthy vaginal microbiota (e.g. lactose, etc.), and/or substances which favorably influence the vaginal environment for the healthy vaginal microbiota (e.g. estradiol, organic acids, etc.). The composition used may be applied locally, preferably in one of the following administration forms: foam, suppository, vaginal tablet, ovule, gel, aerosol, powder, rinse, douche, cream/ointment, or suspension. | 2017-05-18 |
20170136061 | SUPPLEMENTED ANTACID FORMULATION - A supplemented antacid formulation comprising at least one primary component and at least one supplemental component. In one embodiment, a primary component is selected from the group consisting of calcium carbonate, magnesium carbonate, and potassium bicarbonate, and a supplemental component is selected from the group consisting of L-glutamine, deglycyrrhizinated licorice, D-limonene, papain, ginger extract, zinc L-carnosine complex, and a probiotic blend. In one further embodiment, a supplemented antacid formulation comprises a plurality of primary components in combination with a plurality of supplemental components, wherein the primary components are selected from the group consisting of calcium carbonate, magnesium carbonate, and potassium bicarbonate, and the supplemental components are selected from the group consisting of L-glutamine, deglycyrrhizinated licorice, D-limonene, papain, ginger extract, zinc L-carnosine complex, and a probiotic blend. | 2017-05-18 |
20170136062 | METHOD OF MAKING NANOCOMPOSITES OF METAL OXIDE AND REDUCED GRAPHENE OXIDE AND USE FOR CANCER TREATMENT - A facile approach is described to prepare monodisperse Fe | 2017-05-18 |
20170136063 | Methods of Preparing T Cells for T Cell Therapy - Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy. | 2017-05-18 |
20170136064 | Dry Platelet Composition - The invention features a dry platelet composition and methods of making and using the freeze-dried platelet composition. | 2017-05-18 |
20170136065 | MESENCHYMAL STROMAL CELLS FOR TREATING RHEUMATOID ARTHRITIS - The present invention provides a method for treating rheumatoid arthritis comprising the use of mesenchymal stromal cells. | 2017-05-18 |
20170136066 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS - Cells present in processed lipoaspirate tissue are used to treat patients, including patients with renal conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit. | 2017-05-18 |
20170136067 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS - Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit. | 2017-05-18 |
20170136068 | COMPOSITION FOR TREATING ISCHEMIC DISEASES OR NEUROINFLAMMATORY DISEASES CONTAINING NEURAL PROGENITOR CELLS OR SECRETOME THEREOF AS ACTIVE INGREDIENT - The present invention provides a composition for treating ischemic diseases or neuroinflammatory diseases. PSA-NCAM-positive neural progenitor cells used in the present invention promote angiogenesis in injected tissue and inhibit an inflammatory response. The PSA-NCAM-positive neural progenitor cells can be simply isolated by using an anti-PSA-NCAM-antibody, and exhibit excellent angiogenic and anti-inflammatory activities compared with mesenchymal stem cells, and thus can be useful as a composition for effectively treating ischemic diseases caused by a vascular injury and nerve damage diseases caused by inflammation. In addition, a secretome of the neural progenitor cells of the present invention reduces the ischemic injury site and allows a neurological function to recover, and thus can be used as an agent for treating ischemic diseases and degenerative nervous system disorders such as nerve damage diseases caused by inflammation. | 2017-05-18 |
20170136069 | CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS - The present invention relates to a device comprising a cell carrier portion containing regenerative cells, e.g., stem and progenitor cells, and a cell carrier containment portion. The device is useful for the treatment of bone related disorders, including spinal fusion related disorders and long bone or flat bone related defects. The device may be used in conjunction with disclosed automated systems and methods for separating and concentrating regenerative cells. | 2017-05-18 |
20170136070 | Acellular Regenerative Products and Methods of Their Manufacture - An acellular product may be derived from human placenta and may be used in various scenarios for wound healing. Because the product may be acellular, the product may be processed for storage and transportation with minimal degradation. The product may include various scaffolding such as biomaterials or human tissue, and the scaffolding may be infused with various plasmas and agents. The cell-free treatment may maintain the biological activity of many therapeutic agents found within cells and may possess multiple structural components to support cellular attachment. The structural components or scaffolds may function as a reservoir of highly diffusible chemotactic and cellular-programming factors that may be useful to treat injury and disease. In many cases, fibrinogen may be absent, which may reduce scarring. | 2017-05-18 |
20170136071 | Umbilical Tissue Compositions and Methods of Use - Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. | 2017-05-18 |
20170136072 | IL-12 IMMUNOTHERAPY FOR CANCER - Compositions and methods far delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia. | 2017-05-18 |
20170136073 | BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER - Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed. | 2017-05-18 |
20170136074 | PROBIOTIC ARGINOLYTIC ORAL COMPOSITIONS AND METHODS OF MAKING AND USING PROBIOTIC ARGINOLYTIC ORAL COMPOSITIONS - The present disclosure provides methods of using probiotic arginolytic oral compositions including isolated arginolytic bacterial strains to increase arginolytic activity in the oral cavity, increase ammonia-producing bacteria in the oral cavity, and/or to treat and/or prevent oral disorders, such as caries. | 2017-05-18 |
20170136075 | PHARMACEUTICAL COMPOSITION CONTAINING SPIRULINA MAXIMA EXTRACT AS ACTIVE INGREDIENT FOR PREVENTING AND TREATING RETINAL DISEASES | 2017-05-18 |
20170136076 | THERAPEUTIC COMPOSITIONS COMPRISING HERBAL EXTRACTS AND ESSENTIAL OILS FOR SMOKING AND VAPORIZATION - The present invention discloses therapeutic compositions comprising herbal extracts and essential oils for smoking and vaporization useful in the treatment of various symptoms and diseases. More particularly the invention relates to compositions comprising herbal extracts and essential oils capable of providing therapeutic benefits, which helps to improve conditions like cough, cold, pain, energy, relaxation, calmness, digestion, immune system disorders and neurological disorders etc. The invention further relates to methods for treating the same using the compositions of the invention. The invention also discloses method of formulating a blend of herbal CO | 2017-05-18 |
20170136077 | BOTANICAL FORMULATIONS - Disclosed is a topical skin composition, and methods for its use, that includes | 2017-05-18 |
20170136078 | Edible oral strip or wafer dosage form containing ion exchange resin for taste masking - An edible oral film strip dosage form containing an unpalatable basic active pharmaceutical ingredient and an ion exchange resin as a primary taste masking agent, along with an optional acidic agent and further optionally containing one or more secondary taste masking agents is provided. The edible oral film strip dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration. | 2017-05-18 |
20170136079 | Herbal Composition And Process For Preparing Detoxifying Herbal Extract For Snake Bite - This invention relates to a herbal composition and process for preparing a detoxifying herbal extract using the stem bark of the woody liana, | 2017-05-18 |
20170136080 | NOVEL METHOD FOR THE TOPICAL APPLICATION OF VETERINARY AGENTS - The invention relates to compositions and to the methods of administration thereof. More specifically, it relates to an optimised method for the administration of active agents to non-human mammals by means of topical application of pre-determined doses. | 2017-05-18 |